Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Beyer

Showing results (101-110 of 225) with videos related to

Pageof 23
Sort By:
Journal of Thrombosis and Haemostasis : JTH|July 14, 2021
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of AnticoagulationKarlyn A Martin, Jan Beyer-Westendorf, Bruce L Davidson, et al.
Critical Reviews in Oncology/Hematology|November 30, 2020
Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical managementHanno Riess, Peter Verhamme, Jeffrey I Weitz, et al.
Kardiologia Polska|October 13, 2021
Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registryReinhold Kreutz, Gilbert Deray, Jürgen Floege, et al.
British Journal of Clinical Pharmacology|April 21, 2012
Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registryLars Donath, Jörg Lützner, Sebastian Werth, et al.
Minerva Anestesiologica|April 13, 2022
Point of care coagulation management in anesthesiology and critical careLars Heubner, Martin Mirus, Oliver Vicent, et al.
BMC Anesthesiology|March 25, 2026
Viscoelastic point-of-care testing for monitoring unfractionated heparin in critically ill patients: a prospective observational study comparing ClotPro® IN/HI-Test, aPTT and Anti-Xa activityMartin Mirus, Anna Dietze, Oliver Tiebel, et al.
Thrombosis and Haemostasis|February 8, 2003
Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosisSebastian M Schellong, Thomas Schwarz, Kai Halbritter, et al.
The Lancet. Haematology|September 12, 2018
Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort studyKirstine Kobberøe Søgaard, Kasper Adelborg, Bianka Darvalics, et al.
Thrombosis and Haemostasis|January 22, 2016
Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC RegistryJudith Hecker, Sandra Marten, Loretta Keller, et al.
Critical Care (London, England)|June 16, 2022
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysisOlivia S Costa, Stuart J Connolly, Mukul Sharma, et al.
Pageof 23

Showing results (101-110 of 225) with videos related to

Sort By:
Pageof 23
Journal of Thrombosis and Haemostasis : JTH|July 14, 2021
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of AnticoagulationKarlyn A Martin, Jan Beyer-Westendorf, Bruce L Davidson, et al.
Critical Reviews in Oncology/Hematology|November 30, 2020
Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical managementHanno Riess, Peter Verhamme, Jeffrey I Weitz, et al.
Kardiologia Polska|October 13, 2021
Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registryReinhold Kreutz, Gilbert Deray, Jürgen Floege, et al.
British Journal of Clinical Pharmacology|April 21, 2012
Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registryLars Donath, Jörg Lützner, Sebastian Werth, et al.
Minerva Anestesiologica|April 13, 2022
Point of care coagulation management in anesthesiology and critical careLars Heubner, Martin Mirus, Oliver Vicent, et al.
BMC Anesthesiology|March 25, 2026
Viscoelastic point-of-care testing for monitoring unfractionated heparin in critically ill patients: a prospective observational study comparing ClotPro® IN/HI-Test, aPTT and Anti-Xa activityMartin Mirus, Anna Dietze, Oliver Tiebel, et al.
Thrombosis and Haemostasis|February 8, 2003
Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosisSebastian M Schellong, Thomas Schwarz, Kai Halbritter, et al.
The Lancet. Haematology|September 12, 2018
Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort studyKirstine Kobberøe Søgaard, Kasper Adelborg, Bianka Darvalics, et al.
Thrombosis and Haemostasis|January 22, 2016
Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC RegistryJudith Hecker, Sandra Marten, Loretta Keller, et al.
Critical Care (London, England)|June 16, 2022
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysisOlivia S Costa, Stuart J Connolly, Mukul Sharma, et al.
Pageof 23